

1 **A Qualitative Study Exploring the Consumer Experience of Receiving Self-Initiated**
2 **Polygenic Risk Scores from a Third-Party Website**

3

4 Kiara Lowes¹, Kennedy Borle², Lasse Folkersen³, Jehannine Austin^{1,4}

5

6

7 ¹University of British Columbia Department of Medical Genetics, Vancouver, British Columbia, Canada;

8 ²University of British Columbia, Faculty of Graduate and Postdoctoral Studies, Interdisciplinary Studies
9 Program, Vancouver, British Columbia, Canada;

10 ³Danish National Genome Center, Copenhagen Region, Denmark;

11 ⁴Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.

12

13

14 Corresponding author:

15 Jehannine Austin, MSc, PhD

16 jehannine.austin@ubc.ca

17 (604) 875 2000 ext. 5943

18 A3-127 939 W28th Ave

19 Vancouver, British Columbia, Canada

20

21 **ABSTRACT**

22 The number of people accessing their own polygenic risk scores (PRSs) online is rapidly
23 increasing, yet little is known about why people are doing this, how they react to the
24 information, and what they do with it. We conducted a qualitative interview-based study with
25 people who pursued PRSs through Impute.me, to explore their motivations for seeking PRS
26 information, their emotional reactions, and actions taken in response to their results. Using
27 interpretive description, we developed a theoretical model describing the experience of
28 receiving PRSs in a direct-to-consumer (DTC) context. Dissatisfaction with healthcare was an
29 important motivator for seeking PRS information. Participants described having medical
30 concerns dismissed, and experiencing medical distrust, which drove them to self-advocate for
31 their health, which in turn ultimately led them to seek PRSs. Polygenic risk scores were often
32 empowering for participants, but could be distressing when PRS information did not align with
33 participants' perceptions of their personal or family histories. Behavioural changes made in
34 response to PRS results included dietary modifications, changes in vitamin supplementation
35 and talk-based therapy. Our data provides the first qualitative insight into how people's lived
36 experience influence their interactions with DTC PRSs.

37

38 **Keywords:** polygenic risk scores, interpretive description, direct to consumer, medical distrust,
39 health advocacy, behavior change

40

41

42 INTRODUCTION

43 Polygenic risk scores (PRSs) are an emerging technology that have ignited debates in the
44 field of genetics about the possibilities and limitations of genetic testing for complex
45 conditions(1–5). Polygenic risk scores represent a sum of weighted genetic risk factors,
46 providing an estimate of an individual’s genetic predisposition for a complex condition. While
47 PRSs are not yet being provided in clinical settings, there are moves towards the integration of
48 PRSs into clinical care to guide screening and prevention strategies(6). Direct-to-consumer
49 (DTC) PRSs have also become available via third party websites that allow people to upload
50 their genetic information to obtain PRS information(7). Despite the rapid uptake of DTC PRSs,
51 limited research has examined the issues and opportunities related to seeking PRSs in this
52 context.

53 Studies exploring the impacts of other (non-PRS) types of DTC genetic testing (DTC-GT)
54 have reported either no change in health-related distress levels(8–11) or a reduction in
55 anxiety(12). Importantly, many of these studies involved genetic counseling or the provision of
56 *hypothetical* genetic test results, making them less representative of how consumers are
57 accessing their genetic information in reality. Adverse reactions and decisional regret have been
58 reported among people who have self-initiated non-PRS related DTC-GT(13–15). To date, PRS
59 research has mainly focused on contexts where PRSs are provided to individuals with a personal
60 or family history of cancer(16–21) or bipolar disorder(22). When provided in these settings,
61 PRSs have served as an explanation for people’s personal or family history and reduce feelings
62 of self-blame. When provided for conditions that are not tailored towards a family history, PRSs
63 have not been found to elicit high levels of distress, though PRSs in this study were provided

64 through a research protocol with informed consent(23). To our knowledge, only one study has
65 examined the issues related to receiving *self-initiated* DTC PRSs where there is no healthcare
66 provider involvement, finding that >50% of users experienced some degree of negative
67 reaction, with 5% showing signs suggestive of post-traumatic stress disorder related to
68 receiving their result(24).

69 We sought to develop a deeper understanding of the motivations for self-initiating PRS
70 testing and reactions to results through a qualitative, interview-based study.

71

72 **MATERIALS AND METHODS**

73 We conducted a qualitative study in which we interviewed self-initiators of PRSs to gain
74 insight into their experience with seeking and receiving PRSs. An interpretive description
75 approach was used for study design and data analysis. Interviews were conducted and coded by
76 the first author (KL), who was a genetic counseling student at the time, and who identified as
77 female. KL had no prior relationships with any of the research participants. Data interpretation
78 was completed by KL, KB, and JA, who are all genetic counselors who do not provide PRSs
79 clinically. None of the members of the study team who were involved in the collection or
80 analysis of the data had personal experience with receiving personal genetic information via
81 Impute.me. Written and verbal consent were obtained prior to all data collection. This study
82 was approved by the University of British Columbia's Research Ethics Board (H21-01616).

83 Eligibility

84 Study participants were recruited from Impute.me, a not-for-profit website
85 (<https://impute.me>) where users could upload their raw genetic information to obtain PRSs.

86 Participants were eligible if they were (1) at least 19 years of age; (2) fluent in written and
87 spoken English; and (3) had received one or more PRSs through the complex disease module of
88 the website.

89 An email was distributed to all Impute.me users, providing a brief description of the
90 research study followed by a short quantitative questionnaire including demographics,
91 immediate response to PRS results, time elapsed since results were received, and present-day
92 emotional impact of PRS information as measured by the Impact of Event Scale—Revised (IES-
93 R)(25). Respondents were asked to provide their contact information if they wanted to be
94 considered for an interview.

95 Sampling approach

96 We used respondents' questionnaires for purposive sampling to ensure broad
97 representation of experiences (e.g. a range of IES-R scale score) and voices (e.g. participants
98 from diverse racial or gender groups) in our interviews.

99 Interviews

100 One-on-one, semi-structured interviews were conducted via Zoom by the first author.
101 The interview guide (see supplemental material) was developed based on quantitative research
102 previously conducted by the study team(24) to explore motivations for seeking PRSs, and
103 emotional responses and actions taken after receiving PRS results. Interviews were audio-
104 recorded and transcribed verbatim by the first author.

105 Data analysis

106 Interview data was analyzed using interpretive description(26,27), which is a qualitative
107 methodology that builds upon the practice of thematic analysis. Interpretive description

108 analyzes the individual and collective experience of a study population to develop common
109 themes that are assembled into a complex picture. The aim of this methodology is to develop a
110 deep understanding of a human experience so as to inform clinical practice(26).

111 Throughout data collection, regular meetings were held to discuss concepts drawn from
112 the interviews and to revise the interview guide to explore themes more thoroughly. Interview
113 transcripts were coded and catalogued by the first author and reviewed with the study team.
114 Several meetings were held to brainstorm relationships between themes and to build a
115 theoretical model demonstrating the process of receiving DTC PRSs. The model was reviewed
116 with three interview participants, who were asked to provide feedback on whether the model
117 resonated with their experiences. Small changes were made to the model to reflect participant
118 feedback.

119

120 **RESULTS**

121 Participants

122 Of the 56,280 people who were contacted about the study, 209 completed the survey
123 with their contact information indicating their interest in an interview. We invited 23
124 participants to complete an interview and ultimately conducted 11 interviews, ranging from 21
125 to 69 minutes in length. Interviewee demographics are summarized in Table 1.

126 Overview of the theoretical model

127 Figure 1 shows a visual depiction of the theoretical model that was constructed through
128 the study. A core driver for seeking PRS information was dissatisfaction with health care.
129 Specifically, participants expressed that their medical concerns had been ignored (*dismissed*

130 *medical concerns*) and/or felt that they had been inadequately treated by their healthcare
131 providers (*medical distrust*). These experiences resulted in a medical void (*represented in Figure*
132 *1 by the unfilled icon representing a person*) that participants sought to fill through self-
133 advocating for their own health, which led them to seek PRSs. Polygenic risk score information
134 was often validating for participants, though for others, unexpected results led to shock and
135 test-related distress. Many participants reported making behavioural changes, regardless of
136 their reactions to their results.

137 Dissatisfaction with healthcare

138 A main factor that motivated people to seek PRS information was their dissatisfaction
139 with the healthcare that they had received. This dissatisfaction was comprised of two
140 components, medical distrust and dismissed medical concerns.

141 Medical distrust

142 Many participants had experienced illness and felt like their treatment, or lack thereof,
143 had only exacerbated their symptoms, which in turn created a sense of distrust in the medical
144 system.

145 *“They had me filled with all sorts of medications for high blood pressure and*
146 *diabetes and other things, all those things just made me sicker.” – Participant 7*

147 Dismissed medical concerns

148 Participants had experienced health concerns but felt dismissed when they brought
149 these medical concerns to a healthcare provider – this led to dissatisfaction with their
150 healthcare.

151 *“Every time I felt sick I would go to a doctor and they would tell me there’s*
152 *nothing wrong with me.” – Participant 4*

153 Several participants described a diagnostic odyssey which had not resulted in a satisfactory
154 explanation for their illness.

155 *“I think family doctors aren’t really great for this sort of stuff. They have a saying*
156 *about how if you hear hooves think horses not zebras... But then, the problem is*
157 *what if you have an unusual condition? Because the next step is to be dismissive,*
158 *[say] it’s all in your head, or we don’t know what it is.” – Participant 7*

159 Self-advocacy

160 Dissatisfaction with healthcare and unmet healthcare needs left a medical void, that
161 often motivated participants to attempt to fulfill their own needs.

162 *“I kept looking for answers instead of screaming for help... I screamed for help for*
163 *months and no one came.” – Participant 4*

164 As self-described “information seekers,” participants advocated for themselves by seeking out
165 genetic information.

166 *“I’ve always been a generally curious person. So, if it was something that I could*
167 *potentially figure out about myself that I couldn’t otherwise figure out, that’s enough for*
168 *me to be curious about what I could find. Just not knowing would be too hard.” –*
169 *Participant 11*

170 Polygenic risk score information

171 There were varied reasons for why participants looked at specific types of PRSs. Some
172 looked up PRSs for their own diagnoses – many did this for mental health conditions in

173 particular. Participant 5 described their motivation for pursuing a PRS for their mental health
174 condition: *“I wanted to confirm what was already there...it brought me closure.”*
175 Other people targeted their search to conditions that they exhibited symptoms of but did not
176 have a formal diagnosis for, or they sought out PRSs for conditions that were running in their
177 family. Others described looking up PRSs for everything that was offered on Impute.me,
178 regardless of their personal or family history.

179 Validation

180 Overall, participants were satisfied with their PRS results. Some people felt like this
181 information allowed them to better understand themselves and their health.

182 *“It’s like getting myself back... I understand the body I inhabit.” – Participant 3*

183 When participants received results that were consistent with their health history, they felt
184 justified in their concerns.

185 *“When people are dismissive of these things, it’s useful to have something that
186 actually backs you up.” – Participant 7*

187 Participants who had concerns about their family history, found it helpful to have confirmation
188 of their genetic predisposition. Participant 10 described how their PRS reduced the uncertainty
189 surrounding their grandparent’s Alzheimer’s diagnoses:

190 *“[It’s useful] knowing conclusively that I seem to have a higher genetic risk and that it’s
191 not just whatever was in the ground water when my grandparents were growing up.”*

192 Shock/Distress

193 When participants received unexpected results (i.e. those that were not consistent with
194 their personal or family history), they either dismissed them or they experienced shock or

195 distress. When PRSs were perceived to contradict their health history, some participants
196 cognitively rejected their scores, especially those who trusted their diagnoses. Participant 4
197 described how they reconciled their low-risk score for autism:

198 *“[Impute.me calculated a Z score of] like 2.5 and they called that medium or low... To me*
199 *2.5... that’s kind of big, that’s a hell of a risk. 2.5, that’s not low... I already had my*
200 *diagnosis, and it just fits. I like my diagnosis because it helps me explain myself to*
201 *others.”*

202 Other participants experienced uncertainty, doubt or anxiety when their PRS results did not
203 reflect their personal or family history.

204 *“My mother suffers of hypertension but I got a very low score... so is that even*
205 *possible?” – Participant 2*

206 *“I have had a lot of anxiety... and I noticed in the polygenic risk score, it was like*
207 *right in the middle. So I almost thought like, well if I’m as likely as anyone else to*
208 *get it then, you know, what does that say about me? Is there something wrong*
209 *with me?” – Participant 11*

210 Participants who received a high-risk result for a condition that did not run in their family
211 experienced distress – particularly when unexpected results for mental health conditions were
212 received. Participant 6 expressed regretting seeking out a PRS after they received a high-risk
213 score for schizophrenia:

214 *“Unfortunately, I do regret getting a PRS... I would have rather not known. I like*
215 *uncertainty.”*

216 Behavioural change

217 Many interviewees reported making behavioural changes based on their PRS results.
218 Importantly, behavioural changes were not limited to those who perceived themselves to be at
219 high risk. Lifestyle changes included weight loss, dietary modifications, more frequent exercise,
220 changes in supplemental or herbal regimen, sunscreen vigilance, practicing self-care, and
221 therapy. Lifestyle changes involving diet, exercise or supplements were implemented as a
222 preventative measure. Therapy and self-care were used as a means of coping with test-related
223 distress stemming from high risk results. Some participants reported feeling more in control of
224 their health after learning about their genetic predisposition to disease, which motivated them
225 to make lifestyle changes.

226 *“It made me cautious. But it also made me aware and gave me the power to stop*
227 *it.” – Participant 4*

228 Another participant described how their PRS results provided direction with what lifestyle
229 changes to make.

230 *“It pointed me in a direction where I could develop a game plan and figure out,*
231 *you know what I was fighting and what was the rational way of approaching it.”*
232 *– Participant 7*

233 Importantly, not everyone made healthcare changes. One participant felt that their healthy
234 lifestyle left no room for changes, especially in the context of their low-risk results. Another
235 participant made no changes because they did not feel like behavioural changes could offset
236 their genetic risk.

237 *“I feel that I can’t do much because there’s something genetic, right? I can’t do*
238 *much about it.” – Participant 2*

239 DISCUSSION

240 To our knowledge, this is the first qualitative study that has engaged with self-initiators
241 of direct-to-consumer polygenic risk scores. We developed a theoretical model that describes
242 participant's motivations for seeking PRSs, emotional reactions, and actions taken in response
243 to their results. We found that PRS information was often sought as an attempt to compensate
244 for unmet healthcare needs and they accessed this information as a form of self-advocacy. The
245 majority of participants described having a positive experience with receiving PRSs. Polygenic
246 risk scores were often validating for participants, particularly when they aligned with existing
247 personal health concerns or family history. When participants experienced shock and/or
248 distress, it was in relation to the PRS being inconsistent with their expectations. Regardless of
249 their emotional reactions to their results, many participants reported making health-related
250 changes such as dietary modifications, exercise routine, and changes in vitamin
251 supplementation. Elements of our model are supported by the literature, whereas others are
252 more novel findings.

253 Common motivations for pursuing DTC-GT are general curiosity about genetic
254 information, clarification of disease risk, and identifying opportunities for preventative
255 action(24,28,29). While these motivations were among those described by our study
256 participants, dissatisfaction with healthcare was a core motivator for seeking PRS information.
257 Medical distrust has been previously observed in the context of clinical genetic testing(30),
258 however to our knowledge, unmet healthcare needs have not been noted in relation to DTC-
259 GT. However, DTC-GT research has been largely quantitative, and "dissatisfaction with
260 healthcare" or "unmet healthcare needs" do not appear to have been provided as survey

261 response options. Even when given the option of providing a free text response, selecting
262 “curiosity” may have served as a catch all response for those who couldn’t articulate their
263 motivations. This idea is supported by the data gathered in the context of the pre-interview
264 survey in this study. Although most people had indicated that they were motivated by curiosity,
265 during their interviews they described an underlying medical or emotional reason behind their
266 curiosity. This potential connection between dissatisfaction with healthcare and DTC-GT
267 warrants further exploration.

268 Our findings suggest that the overall experience with receiving PRSs in a DTC setting is
269 largely positive. Many participants reported feeling validated by their results, particularly when
270 their PRS results aligned with their personal or family history. Participants who received a high-
271 risk score for a pre-existing condition appreciated having an explanation for their diagnoses.
272 While we did not select participants for particular diagnoses, many interview participants were
273 neurodiverse and/or had a history of mental illness. This observation creates an interesting
274 picture when combined with data from previous work showing that psychiatric diagnoses are
275 among the most commonly sought PRSs(7), and data showing that people with these diagnoses
276 are likely to have unmet health care needs(31,32). People who received a high-risk result for a
277 condition that ran in their family were relieved to have confirmation of their genetic risk. When
278 results were not consistent with participant’s personal or family history, many participants
279 found reasons to dismiss or discredit these results. This indicates a role for confirmation bias in
280 responses to self-initiated PRS. This is supported by previous work which has identified
281 confirmation bias as relevant reactions to other types of genetic testing(33,34).

282 Despite describing their experiences as positive, many participants reflected on negative
283 emotions associated with their results. Negative emotions included shock, confusion, anxiety,
284 and concern. The potential for negative reactions contrasts with clinical PRS research that
285 describes mainly positive experiences(16–19,21–23). It is possible that the negative reactions
286 our research showed were mitigated in other studies by the involvement of a healthcare
287 provider in pre-test or post-test counseling. Additionally, prior studies provided targeted PRSs
288 to individuals with a personal or family history of cancer(16–21) or bipolar disorder(22). It is
289 possible that having a family history may lead to an overestimation of perceived genetic risk,
290 reducing the burden of a PRS. Rather than receiving targeted PRSs, our participants had a broad
291 range of PRSs available to them, which may explain why more participants reacted negatively to
292 their results. Negative outcomes have also been observed for other DTC third-party
293 interpretation tools(35).

294 Regardless of participant’s emotional reactions to their results, almost all participants
295 reported making health-related changes in response to their results. As mentioned, behavioural
296 changes were not limited to those who received high-risk results. For many, high-risk results
297 provided motivation to make behavioural changes as an attempt to prevent the onset of
298 disease. Alternatively, low-risk results for pre-existing conditions motivated others to re-
299 evaluate their lifestyle choices. People who did not make lifestyle adjustments were already
300 engaging in healthy behaviours or were not convinced that lifestyle changes could reduce their
301 overall risk. Participants engaged in behavioural changes if they could identify areas in which to
302 improve and when they believed it would make a difference. Our findings contrast with
303 previous PRS research which did not identify behavioural changes made in response to PRS

304 information(23,36). It is possible that our study participants were more motivated to make
305 behavioural changes given that their healthcare experiences left them in a state of need.

306 This study has several limitations. Purposive sampling was used to recruit a
307 demographically diverse group of interviewees. Despite our best efforts, over half of our
308 interview participants were White, in part because the majority Impute.me users are White.
309 Also, because Impute.me users have to overcome the barrier of obtaining and uploading raw
310 genetic information that they received from another source, this population may be considered
311 “early adopters” of this technology and may not represent the average experience with PRS
312 information. Additionally, in accordance with Impute.me’s commitment to preserve anonymity,
313 the researchers did not have access to participant’s PRS results and were unable to evaluate
314 people’s understanding of their results, which could have been useful context for
315 understanding their reactions and responses to their genetic information.

316 Our research identified a novel relationship between dissatisfaction with healthcare and
317 DTC-GT. More research is needed to explore this finding and moreover, to investigate what
318 underlies “general curiosity” about genetic information. Additionally, as PRSs become
319 incorporated into clinical settings, it will become increasingly important to understand
320 predictors of adverse reactions to PRSs.

321 We developed a theoretical model describing how unmet healthcare needs and self-
322 advocacy can motivate PRS-seeking behaviour. How people reacted to their results depended
323 on whether their results aligned with their expectations, which were shaped by their lived
324 experience with each condition. Participants used PRSs to inform health-related behavior
325 decisions. The novel relationship between dissatisfaction with healthcare, unmet need, self-

326 advocacy, and PRSs is important to consider as PRS become integrated into clinical care to
327 maximize the benefit and minimize the harms of PRS information.

328

329 **DATA AVAILABILITY STATEMENT**

330 Original qualitative data will not be made publicly available to protect the privacy of
331 research participants.

332

333 **CODE AVAILABILITY**

334 Data analyzed through the study is available in the published manuscript. Raw and
335 coded data will not be made available to protect the privacy of research participants

336

337

338

339

340

341

342

343

344

345

346

347

348 **REFERENCES**

- 349 1. Lewis CM, Vassos E. Prospects for using risk scores in polygenic medicine. *Genome Med.*
350 2017;9(1):9–11.
- 351 2. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk
352 scores. *Nat Rev Genet* [Internet]. 2018;19(9):581–90. Available from:
353 <http://dx.doi.org/10.1038/s41576-018-0018-x>
- 354 3. Duncan L, Shen H, Gelaye B, Meijssen J, Ressler K, Feldman M, et al. Analysis of polygenic
355 risk score usage and performance in diverse human populations. *Nat Commun* [Internet].
356 2019;10(1). Available from: <http://dx.doi.org/10.1038/s41467-019-11112-0>
- 357 4. Adeyemo A, Balaconis MK, Darnes DR, Fatumo S, Granados Moreno P, Hodonsky CJ, et al.
358 Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.
359 *Nat Med.* 2021;27(11):1876–84.
- 360 5. Lewis ACF, Green RC, Vassy JL. Polygenic risk scores in the clinic: Translating risk into
361 action. *Hum Genet Genomics Adv* [Internet]. 2021;2(4):100047. Available from:
362 <https://doi.org/10.1016/j.xhgg.2021.100047>
- 363 6. Khera A V., Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide
364 polygenic scores for common diseases identify individuals with risk equivalent to
365 monogenic mutations. *Nat Genet* [Internet]. 2018;50(9):1219–24. Available from:
366 <http://dx.doi.org/10.1038/s41588-018-0183-z>
- 367 7. Folkersen L, Pain O, Ingason A, Werge T, Lewis CM, Austin J. Impute.me: An Open-Source,
368 Non-profit Tool for Using Data From Direct-to-Consumer Genetic Testing to Calculate and
369 Interpret Polygenic Risk Scores. *Front Genet.* 2020;11(June):1–11.

- 370 8. Roberts JS, Ostergren J. Direct-to-Consumer Genetic Testing and Personal Genomics
371 Services: A Review of Recent Empirical Studies. *Curr Genet Med Rep.* 2013;1(3):182–200.
- 372 9. Covolo L, Rubinelli S, Ceretti E, Gelatti U. Internet-based direct-to-consumer genetic
373 testing: A systematic review. *J Med Internet Res.* 2015;17(12).
- 374 10. Stewart KFJ, Wesselius A, Schreurs MAC, Schols AMWJ, Zeegers MP. Behavioural
375 changes, sharing behaviour and psychological responses after receiving direct-to-
376 consumer genetic test results: a systematic review and meta-analysis. *J Community*
377 *Genet.* 2018;9(1):1–18.
- 378 11. James KM, Cowl CT, Tilburt JC, Sinicropo PS, Robinson ME, Frimansdottir KR, et al.
379 Impact of direct-to-consumer predictive genomic testing on risk perception and worry
380 among patients receiving routine care in a preventive health clinic. *Mayo Clin Proc.*
381 2011;86(10):933–40.
- 382 12. Egglestone C, Morris A, O'Brien A. Effect of direct-to-consumer genetic tests on health
383 behaviour and anxiety: A survey of consumers and potential consumers. *J Genet Couns.*
384 2013;22(5):565–75.
- 385 13. Roberts JS, Gornick MC, Carere DA, Uhlmann WR, Ruffin MT, Green RC. Direct-to-
386 consumer genetic testing: User motivations, decision making, and perceived utility of
387 results. *Public Health Genomics.* 2017;20(1):36–45.
- 388 14. Carere DA, Kraft P, Kaphingst KA, Roberts JS, Green RC. Consumers report lower
389 confidence in their genetics knowledge following direct-to-consumer personal genomic
390 testing. *Genet Med.* 2016;18(1):65–72.
- 391 15. Kaphingst KA, McBride CM, Wade C, Alford SH, Reid R, Larson E, et al. Patients

- 392 understanding of and responses to multiplex genetic susceptibility test results. *Genet*
393 *Med.* 2012;14(7):681–7.
- 394 16. Smit AK, Newson AJ, Best M, Badcock CA, Butow PN, Kirk J, et al. Distress, uncertainty,
395 and positive experiences associated with receiving information on personal genomic risk
396 of melanoma. *Eur J Hum Genet* [Internet]. 2018;26(8):1094–100. Available from:
397 <http://dx.doi.org/10.1038/s41431-018-0145-z>
- 398 17. Young MA, Forrest LE, Rasmussen VM, James P, Mitchell G, Sawyer SD, et al. Making
399 Sense of SNPs: Women’s Understanding and Experiences of Receiving a Personalized
400 Profile of Their Breast Cancer Risks. *J Genet Couns.* 2018;27(3):702–8.
- 401 18. Bancroft EK, Castro E, Bancroft GA, Ardern-Jones A, Moynihan C, Page E, et al. The
402 psychological impact of undergoing genetic-risk profiling in men with a family history of
403 prostate cancer. *Psychooncology.* 2015;24(11):1492–9.
- 404 19. Yanes T, Kaur R, Meiser B, Scheepers-Joynt M, McInerney S, Barlow-Stewart K, et al.
405 Women’s responses and understanding of polygenic breast cancer risk information. *Fam*
406 *Cancer* [Internet]. 2020;19(4):297–306. Available from: [https://doi.org/10.1007/s10689-](https://doi.org/10.1007/s10689-020-00185-2)
407 [020-00185-2](https://doi.org/10.1007/s10689-020-00185-2)
- 408 20. Willis AM, Smith SK, Meiser B, James PA, Ballinger ML, Thomas DM, et al. Influence of
409 lived experience on risk perception among women who received a breast cancer
410 polygenic risk score: ‘Another piece of the pie.’ *J Genet Couns.* 2021;30(3):849–60.
- 411 21. Yanes T, Meiser B, Kaur R, Young MA, Mitchell PB, Scheepers-Joynt M, et al. Breast
412 cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes
413 and risk management behavior. *Genet Med* [Internet]. 2021;23(12):2316–23. Available

- 414 from: <https://doi.org/10.1038/s41436-021-01288-6>
- 415 22. Putt S, Yanes T, Meiser B, Kaur R, Fullerton JM, Barlow-Stewart K, et al. Exploration of
416 experiences with and understanding of polygenic risk scores for bipolar disorder. *J Affect*
417 *Disord* [Internet]. 2020;265(June 2019):342–50. Available from:
418 <https://doi.org/10.1016/j.jad.2020.01.037>
- 419 23. Bloss CS, Schork NJ, Topol EJ. Effect of Direct-to-Consumer Genomewide Profiling to
420 Assess Disease Risk. *N Engl J Med*. 2011;364(6):524–34.
- 421 24. Peck L, Borle K, Folkersen L, Austin J. Why do people seek out polygenic risk scores for
422 complex disorders, and how do they understand and react to results? *Eur J Hum Genet*.
423 2022;30(1):81–7.
- 424 25. Christianson S, Marren J. The Impact of Event Scale - Revised (IES-R). *Medsurg Nurs*.
425 2012;21(5):321–2.
- 426 26. Thorne S, Kirkham SR, O’Flynn-Magee K. The Analytic Challenge in Interpretive
427 Description. *Int J Qual Methods*. 2004;3(1):1–11.
- 428 27. Thorne S. Beyond theming: Making qualitative studies matter. *Nurs Inq*. 2020;27(1):1–2.
- 429 28. Gerdes AM, Nicolaisen L, Husum E, Andersen JB, Gantzhorn MD, Roos L, et al. Direct to
430 consumer genetic testing in Denmark—public knowledge, use, and attitudes. *Eur J Hum*
431 *Genet* [Internet]. 2021;29(5):851–60. Available from: [http://dx.doi.org/10.1038/s41431-](http://dx.doi.org/10.1038/s41431-021-00810-3)
432 [021-00810-3](http://dx.doi.org/10.1038/s41431-021-00810-3)
- 433 29. Gollust SE, Gordon ES, Zayac C, Griffin G, Christman MF, Pyeritz RE, et al. Motivations and
434 perceptions of early adopters of personalized genomics: Perspectives from research
435 participants. *Public Health Genomics*. 2011;15(1):22–30.

- 436 30. Angelo F, Veenstra D, Knerr S, Devine B. Prevalence and prediction of medical distrust in
437 a diverse medical genomic research sample. *Genet Med* [Internet]. 2022;1–9. Available
438 from: <https://doi.org/10.1016/j.gim.2022.03.007>
- 439 31. Nicolaidis C, Raymaker D, McDonald K, Dern S, Boisclair WC, Ashkenazy E, et al.
440 Comparison of healthcare experiences in autistic and non-autistic adults: A cross-
441 sectional online survey facilitated by an academic-community partnership. *J Gen Intern*
442 *Med*. 2013;28(6):761–9.
- 443 32. Fortuna KL, Ferron J, Pratt SI, Muralidharan A, Aschbrenner KA, Williams AM, et al.
444 Unmet Needs of People with Serious Mental Illness: Perspectives from Certified Peer
445 Specialists. *Psychiatr Q*. 2019;90(3):579–86.
- 446 33. Lebowitz MS, Ahn WK. Testing positive for a genetic predisposition to depression
447 magnifies retrospective memory for depressive symptoms. *J Consult Clin Psychol*.
448 2017;85(11):1052–63.
- 449 34. Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype
450 on subjective and objective memory performance in healthy older adults. *Am J*
451 *Psychiatry*. 2014;171(2):201–8.
- 452 35. Nelson SC, Bowen DJ, Fullerton SM. Third-Party Genetic Interpretation Tools: A Mixed-
453 Methods Study of Consumer Motivation and Behavior. *Am J Hum Genet* [Internet].
454 2019;105(1):122–31. Available from: <https://doi.org/10.1016/j.ajhg.2019.05.014>
- 455 36. Bloss CS, Wineinger NE, Darst BF, Schork NJ, Topol EJ. Impact of direct-to-consumer
456 genomic testing at long term follow-up. *J Med Genet*. 2013;50(6):393–400.
- 457

458 **FIGURE LEGENDS**

459 **Figure 1.** A visual representation of the process of obtaining polygenic risk scores (PRSs),
460 beginning with the motivations for pursuing PRS information, how participants reacted to their
461 results, and what they did with their results. Various arrow weights are used to demonstrate
462 major and minor pathways taken by participants; thick arrows represent common routes and
463 thin arrows represent less common routes. Dashed arrows are used to indicate routes that not
464 everyone takes; this process may end with an emotional response, or some may proceed to
465 make behavioural changes in response to their PRS results.

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480 **ACKNOWLEDGEMENTS**

481 The authors offer gratitude to the Coast Salish Peoples, including the x̱m̱θkw̱y̱m̱
482 (Musqueam), Skwxwú7mesh (Squamish), and Səḻílw̱ta̱/Selilwitulh (Tseil-Waututh) Nations,
483 on whose traditional, unceded and ancestral territory we have the privilege of working.

484

485 **AUTHOR CONTRIBUTIONS**

486 All authors contributed to the design and execution of the study, and the drafting,
487 revision, and final approval of the manuscript. KL, KB, and JA contributed to the analysis and
488 interpretation of the data.

489

490 **FUNDING**

491 This research was supported by research grants from the National Society of Genetic
492 Counselors Precision Medicine Special Interest Group and the University of British Columbia
493 and was conducted to fulfill a degree requirement as part of training. JA was supported by the
494 Canada Research Chairs program, and BC Mental Health and Substance Use Services. The
495 funders had no role in review or approval of the manuscript.

496

497 **ETHICAL APPROVAL**

498 All procedures followed were in accordance with the ethical standards of the University
499 of British Columbia. Informed consent was obtained from all individual participants included in
500 the study. The study was approved by the University of British Columbia's Research Ethics
501 Board (H21-01616).


502

503 **COMPETING INTERESTS**

504 KL and KB declare no conflicts of interest. Dr. Lasse Folkersen is the founder of
505 Impute.me and Dr. Jehannine Austin provided consultation for the website, though neither
506 made a profit from this service. Dr. Austin also provides consultation for 23andme. The
507 voluntary donations received by Impute.me go to a registered company, from where it is used
508 to pay for server costs. Impute.me was a Danish-law IVS company with ID 37918806, financially
509 audited under Danish tax law.

FIGURES

Figure 1



TABLES

Table 1. Demographics of interview participants.

	Participants (n=11)
Sex	
Male	4
Female	7
Gender	
Man	5
Woman	4
Non-Binary	1
Genderfluid	1
Transgender	
Yes	1
Age (years)	
Mean	36
Range	20-62
Race^a	
Black	1
East Asian	0
Southeast Asian	0
Indigenous/Aboriginal	1
Latino	1
Middle Eastern	1
South Asian	1
White	7
Prefer to self-describe: Ashkenazi Jewish	1
IES score	
Mean	9.6
Range	0-41
Time since results (weeks)	
Mean	66
Range	2-156
Main condition(s) searched^b	
Irritable bowel syndrome	1
Depression	1
Atrial fibrillation	1
Lupus	2
Dementia	2
Breast cancer	1
Schizophrenia	1
Stroke	1
Narcolepsy	1
Asthma	1

^a Participants could select more than one race category.

^b Participants could describe more than one condition that they received a PRS for.